

**INFORMATION DISCLOSURE STATEMENT**

(37 C.F.R. 1.56, 1.97, and 1.98)

SHEET 1 OF 2

ATTORNEY DOCKET

23164-1001

APPLICATION NO.

08/853,870

APPLICANT(S)

Tovey, Michael G.

FILING DATE

May 9, 1997

GROUP


1205

U.S. PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
	A	4,605,555	8/86	Sato et al	424/85	
	B	5,019,382	5/91	Cummins, Jr.	424/85.4	
	C	5,215,741	6/93	Young et al.	424/85.7	
	D	5,286,748	2/94	Eby, III	514/494	

OTHER DOCUMENTS

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
	E	Boguniewicz et al., "The Effect of Nebulized Recombinant Interferon- γ in Asthmatic Airways", <i>J. Allergy Clin. Immunol.</i> 95 :133-135 (1995).
	F	Brod et al., "Oral Administration of IFN- α is Superior to Subcutaneous Administration of IFN- α in the Suppression of Chronic...", <i>Journal of Autoimmunity</i> 9 :11-20 (1996).
	G	Douglas et al., "Prophylactic Efficacy of Intranasal Alpha ₂ -Interferon Against Rhinovirus Infections in the Family Setting" 314 : 65-70 (1986).
	H	Hayden et al., "Intranasal Interferon α_2 for Prevention of Rhinovirus Infection and Illness", <i>Journal of Infectious Diseases</i> 148 :543-550 (1983).
	I	Hayden et al., "Human Tolerance and Histopathologic Effects of Long Term Administration of Intranasal Interferon- α_2 ", <i>Journal of Infectious Diseases</i> 148 :914-921 (1983).
	J	Hayden et al., "Prevention of Natural colds by Contact Prophylaxis with Intranasal Alpha ₂ -Interferon", <i>New England Journal Of Medicine</i> 314 :71-75 (1986).
	K	Hayden et al., "Human Nasal Mucosal Responses to Topically Applied Recombinant Leukocyte A Interferon", <i>Journal of Infectious Diseases</i> 156 :64-72 (1987).
	L	Iida et al., "Protective Activity of Recombinant Cytokines Against Sendai Virus and Herpes Simplex Virus (HSV) infections in mice", <i>Vaccine</i> 7 :229-233 (1989).
	M	Machida et al., "Absorption of Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) from Rat Nasal Mucosa", <i>Pharmaceutical Research</i> 10 :1372-1377 (1993).
	N	Matsuzawa et al., "Protective Effect of Mucosal Administration of Recombinant Human Macrophage Colony-Stimulating Factor...", <i>Vaccine</i> 15 :85-89 (1997).
	O	Oehling et al., "Suppression of the Immune System by Oral Glucocorticoid Therapy in Bronchial Asthma", <i>Allergy</i> 52 :144-154.
	P	Samo et al., "Efficacy and Tolerance of Intranasally Applied Recombinant Leukocyte A Interferon in Normal Volunteers", <i>Journal of Infectious Diseases</i> 148 :535-542 (1983).
	Q	Samo et al., "Intranasally Applied Recombinant Leukocyte A Interferon in Normal Volunteers. II.", <i>Journal of Infectious Diseases</i> 150 :181-188 (1984).
	R	Soos et al., Oral Feeding of Interferon τ Can Prevent the Acute and Chronic Relapsing Forms of



		Experimental Allergic Encephalomyelitis", <i>Journal of Neuroimmunology</i> 75:43-50 (1997).
Q	S -	Takada et al., "Pharmacological Activity of Tablets Containing Recombinant Human Granulocyte...", <i>International Journal of Pharmaceutics</i> 101:89-96 (1994).
Q	T -	Vriesendorp et al., "Oral Administration of Type I Interferon Modulates the Course of Experimental Allergic Neuritis", <i>Autoimmunity</i> 24:157-165 (1996).
Q	U -	Watanabe et al., "Absorption and Blood Leukocyte Dynamics of Recombinant Human Granulocyte Colony-Stimulating Factor...", <i>International Journal of Pharmaceutics</i> 110:93-97 (1994).
Q	V -	Zielinska et al., "Comparison of the Long-Term Effects of Treatment with Oral and Parenteral...", <i>Archivum Immunologiae et Therapiae Experimentalis</i> 44:359-366 (1996).
EXAMINER'S SIGNATURE		DATE CONSIDERED
		7/17/98
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.		